Background: Several randomized phase III trials in neuroendocrine tumors (NETs) 
Introduction
Neuroendocrine tumors (NET) arise from cells of the endocrine (hormonal) and nervous systems. NETs are considered a rare disease even their incidence appear to be increasing The aim of this study is to analyse the available clinical data from randomized controlled trials (RCTs) looking for efficacy of target agents in patients with advanced NETs.
Materials and methods

Data retrieval strategies
We conducted the meta-analysis of randomized studies in accordance with the PRISMA guidelines [13] . The databases of PubMed/MEDLINE, the Cochrane Library, and the American society of clinical oncology (ASCO) Meeting were searched for relevant publications using the following terms: ""Neuroendocrine tumour"" or ""NET"" or ""Carcinoid tumours"" and "target therapy" or "sunitinib" or "everolimus" or "bevacizumab". The publications that were available in these databases up to December 31, 2015, were analysed. The search was restricted to human studies, and the search criteria were limited to phase II or phase III trials. The computer search was supplemented with manual searches of the references listed in all of the retrieved review articles, including primary studies. When the results of a study were reported in subsequent interim analysis, only the most recent or complete and updated version was included in the analysis.
Inclusion criteria
The studies were identified according to the following inclusion criteria: 1) human participants with a NET; 2) a targeted agent therapy alone or in combination for experimental arm; 3) the presence of a control for comparison (placebo or not); 4) a primary outcome of response expressed as the hazard ratio (HR) for either PFS or overall survival (OS), as well as the response rate expressed as relative risk (RR). The following exclusion criteria were used: 1) insufficient data were available to estimate the outcomes;
2) animal studies; 3) the size of each arm was fewer than 10 participants; and 4) the presence of a single-arm study.
Data extraction
LZ and SV independently extracted the relevant data of each trials, including the name of the first author, country, publication year, characteristics of the enrolled patients, median follow-up and information about the study design (i.e., the type of blinding, type of control, and methods for randomization allocation), survival outcomes expressed as HRs for OS and PFS, and the number of patients who experienced a response rate with a grade 3-4 adverse event. The arm with the targeted agent has been considered as the experimental.
For the time-to-event variables (OS or PFS), HRs with the 95% confidence intervals (95%CIs) were calculated for each study. For the dichotomous variables (partial or complete response rate and toxicity) RRs with the 95% CIs were calculated for each study.
Quality assessment and statistical analysis
The methodological quality of each included study was assessed by two independent researchers (GA and PC). The study quality was assessed using the Jadad 5-item scale.
The final score ranged from 0 to 5 [14] . Disagreements were evaluated by the kappa test, and consensus was achieved in discussion with the corresponding author (GR).
Statistical analysis
Statistical analyses were performed using Revman 5.3. The summary estimates were generated using a fixed-effects model (Mantel-Haenszel method) or a random-effects 
Results
Literature review, characteristics and quality of the included studies
The search yielded 8454 potentially relevant articles. (Table 1) .
Efficacy data
Data about OS and PFS were reported in Table 2 In the subgroup analysis, we have reported a better PFS in patients with pancreatic NETs versus other site of NETs (HR=0.49 and 0.71 respectively). However, it is well known for chemotherapy and targeted treatment than better response is observed for pancreatic NETs than non-pancreatic NETs. Therefore our study empowered this issue.
The identification of the patients who will benefit or will be resistant to targeted agents is mandatory in a clinical setting. Unfortunately, there are less established biomarkers able to predict the response of advanced NETs to targeted agents. In the near future, studies 
Conclusions
NETs are a heterogeneous disease leading to a very difficult trial design and algorithm of therapy. Therefore, the optimal management of advanced NETs is still a challenge for medical oncologist. The recent success of phase III trials demonstrate that the novel agents such as sunitinib, and everolimus are an effective therapeutic options for patients with advanced NETs with particular regards to the pancreatic tumors. While, the combination of everolimus plus octreotide LAR improves PFS in patients with advanced
NETs, no data are available on the antitumor activity of the combination of sunitinib and everolimus or sunitinb octreotide and LAR. Nowadays, new pathways with new targeted therapies are under investigation in advanced NETs, but it is still mandatory to design and conduct trials properly to solve the issue of the optimal management in any subgroups of advanced NETs, maybe thankful also the identification of "driver" biomarker for selected treatment. 
